$STRS

Mon: TASE claws back strong early losses

Israel and Iran reportedly agreed to stop hostilities under US pressure, helping the Tel Aviv Stock Exchange rebound from early losses. The TA-35 rose 0.33% to 4,281.85 and TA-125 rose 0.01% to 4,232.14; BlueTech Global fell 0.86% to 696.72. Insurance gained 2.2%; TelBond 60 was flat. Turnover: NIS 4.80b equities, NIS 5.43b bonds. Shekel strengthened to NIS 2.943/$ and NIS 3.39/€.

Original reporting
Published Jun 9, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mon: TASE claws back strong early losses — source image
Decision brief

The 30-second read

$STRSBullishLow
01

Why it matters

The newest concrete fact is the market’s reaction to cease-hostilities clarity; company moves are presented as part of that tape rather than standalone fundamentals.

02

Market read

Useful for gauging intraday risk sentiment and which Tel Aviv sectors/names are trading as proxies, but it contains no new issuer-specific fundamentals.

03

What to watch

The article is a market wrap with no company-specific catalysts; traders should treat moves as correlation trades and wait for follow-through from subsequent sessions or filings.

Relevance 4/10Novelty 2/10Timing: during the Tel Aviv session (morning losses then rebound)

Background

The session is framed around a shift in Israel-Iran hostilities expectations after US pressure, with indices mixed and turnover reported.

Company-level read

Ticker impact

$STRSBullishLow confidence
Context

Strauss Group jumped 4.19%, the biggest rise on the Tel Aviv 35 Index during the market’s recovery from early losses.

Expected impact

Momentum may persist intraday, but reversal risk is elevated without a fundamental trigger.

Evidence & confidence

The article frames the move within the broader market rebound; no new Strauss disclosure.

$ENLTBullishLow confidence
Context

Enlight Renewable Energy rose 1.08% during the rebound, with no separate company-specific development cited.

Expected impact

Limited conviction beyond market beta.

Evidence & confidence

The text provides only an intraday move and macro backdrop.

$ESLTBullishLow confidence
Context

Elbit Systems rose 1.89% as the market recovered on expectations of reduced hostilities between Israel and Iran.

Expected impact

Short-term upside while de-escalation holds; could reverse if security risk returns.

Evidence & confidence

Move is plausibly macro-driven; no Elbit-specific disclosure is included.

$TEVABullishLow confidence
Context

Teva Pharmaceutical rose 2.26% during the rebound after Israel-Iran cease-hostilities clarity under US pressure.

Expected impact

Near-term support if risk sentiment stays constructive.

Evidence & confidence

Only same-day price action is reported; catalyst is macro.

$TSEMBearishLow confidence
Context

Tower Semiconductor fell 4.73% for the biggest drop on the Tel Aviv 35 Index despite the overall market rebound.

Expected impact

Higher volatility/mean-reversion risk; direction depends on whether the selloff is headline- or flow-driven.

Evidence & confidence

The text cites only the intraday decline and macro backdrop, without a TSEM catalyst.

$CAMTBearishLow confidence
Context

Camtek fell 2.33% as the Tel Aviv market was mixed, with some names diverging from the rebound.

Expected impact

Could stabilize if broader risk-on continues; otherwise may lag.

Evidence & confidence

No company-specific information beyond the price move.

$ICLBearishLow confidence
Context

ICL fell 1.49% as Tower Semiconductor and other names declined while the broader market recovered.

Expected impact

Choppy near-term; watch for correlation with regional risk headlines.

Evidence & confidence

The article provides no ICL-specific news beyond the price move.

Market effects

Insurance strength (Insurance Index +2.2%) and divergence in defense/industrial names suggest sector rotation tied to regional risk sentiment.

Tel Aviv indices recovered after US pressure led Israel and Iran to cease hostilities, improving near-term risk appetite.

Limited direct global spillover in the text; primarily a regional risk-sentiment read-through.

Counterpoint

The rebound may be headline-driven and therefore fragile; single-name divergence (e.g., TSEM -4.73%) hints at positioning/sector flows beyond the macro de-escalation story.

Key entities

  • Tel Aviv Stock Exchange

    Indices recovered from early losses after cease-hostilities clarity between Israel and Iran.

  • Israel and Iran

    Bowed to US pressure to cease hostilities, driving risk sentiment in Tel Aviv.

Related articles

$TEVAMedAI 8/10

Teva (TEVA) Q2 2026 Earnings Call Transcript

Teva (TEVA) reported Q2 2026 revenue of $4.1B, down 1% year over year due to lower U.S. generic sales. Innovative brands rose, including AUSTEDO $696M (+40%), AJOVY $244M (+56%), and UZEDY $77M (+43%). Non-GAAP EPS was $0.02 and free cash flow was $622M (+31%). 2026 revenue guidance was raised to $16.5B-$16.85B; net debt was $12.9B (2.8x).

$TSEMMed

Here's Why Tower Semiconductor Stock Is Rocketing Higher Today

Tower Semiconductor (TSEM) shares rose 8.9% to about 11:15 a.m. ET after Bank of America initiated coverage with a buy rating and a $367 price target, implying 63% upside. Bank of America cited Tower’s market-leading silicon photonics position and projected SiPho revenue doubling in 2026. Tower reported Q2 2026 record revenue of $460 million (+24% YoY) and net income of $91 million (+95%).

$TSEMMedAI 8/10

Tower Semiconductor Ltd. Q2 2026 Earnings Call Summary

Tower Semiconductor reported Q2 2026 record profitability, citing 30% gross and 20% net margins, higher silicon photonics revenue (+270% YoY to a $680m annualized run rate) and capacity investments. It plans dual-track Japan 300mm expansion, updates its 2028 model to $3.6b revenue and 33% net margin, and guided Q3 2026 revenue to $520m midrange.

$ICLMed

ICL reports Q2 2026 sales higher by 17% to $2.1 billion

ICL reported Q2 2026 sales of $2.1 billion, up 17% from $1.8 billion a year earlier, citing stronger pricing and demand. Operating income rose to $266 million from $181 million, and net income to $137 million from $93 million. Adjusted EBITDA was $448 million. ICL reiterated FY2026 adjusted EBITDA guidance of $1.5 billion to $1.7 billion and potash volumes of 4.5 to 4.7 million metric tons.

$ICLMedAI 8/10

ICL (ICL) Q2 2026 Earnings Call Transcript

ICL Group reported Q2 2026 sales of $2.1 billion, up 17%, and adjusted EBITDA of $448 million, up 28%, citing higher potash, bromine and phosphate prices. Adjusted net income rose 35% to $149 million, and adjusted EPS rose 33% to $0.12. Free cash flow was $94 million. Full-year 2026 EBITDA guidance was reiterated at $1.5 billion to $1.7 billion.

$ICLMedAI 8/10

ICL Group LTD: ICL Reports Second Quarter 2026 Results

ICL Group (NYSE: ICL) reported Q2 2026 results for the quarter ended June 30, 2026. Consolidated sales rose to $2.1 billion (+17% Y/Y). Operating income increased to $266 million from $181 million, and net income attributable to shareholders rose to $137 million from $93 million. ICL reiterated FY2026 adjusted EBITDA guidance of $1.5B to $1.7B and expects potash volumes of 4.5 to 4.7 million metric tons.